Puma Biotechnology News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.01.25	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
23.12.24	Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation (Businesswire)
04.12.24	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
20.11.24	Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer (Businesswire)
07.11.24	Puma Biotechnology Reports Third Quarter 2024 Financial Results (Businesswire)
05.11.24	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
24.10.24	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Businesswire)
03.09.24	Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
06.08.24	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
01.08.24	Puma Biotechnology Reports Second Quarter Financial Results (Businesswire)
18.07.24	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results (Businesswire)
02.07.24	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.06.24	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.06.24	Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer (Businesswire)
02.06.24	Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) (Businesswire)
28.05.24	Puma Biotechnology to Join Russell 3000 Index (Businesswire)
23.05.24	Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting (Businesswire)
02.05.24	Puma Biotechnology Reports First Quarter Financial Results (Businesswire)
18.04.24	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results (Businesswire)
03.04.24	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
20.03.24	Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer (Businesswire)
29.02.24	Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
28.02.24	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
15.02.24	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
13.02.24	Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	61.88	2.93 %	K V
Swiss Re	130.20	1.92 %	K V
UBS Group	33.02	1.38 %	K V
Kuehne+Nagel Int	190.90	1.11 %	K V
ABB	70.20	0.98 %	K V
Novartis	122.74	-0.29 %	K V
Givaudan	3’058.00	-0.75 %	K V
Logitech Intl	68.68	-4.40 %	K V
Holcim	72.38	-5.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Puma Biotechnology Aktie VALOR 18238887 / ISIN US74587V1070

Nachrichten zu Puma Biotechnology Inc

Aktien Top/Flop

Meistgelesene Nachrichten